Skip to main content
AAN.com

Abstract

Objective:

To determine whether calcium supplementation is associated with the development of dementia in women after a 5-year follow-up.

Methods:

This was a longitudinal population-based study. The sample was derived from the Prospective Population Study of Women and H70 Birth Cohort Study in Gothenburg, Sweden, and included 700 dementia-free women aged 70–92 years. At baseline in 2000–2001, and at follow-up in 2005–2006, the women underwent comprehensive neuropsychiatric and somatic examinations. A CT scan was performed in 447 participants at baseline. Information on the use and dosage of calcium supplements was collected. Dementia was diagnosed according to DSM-III-R criteria.

Results:

Women treated with calcium supplements (n = 98) were at a higher risk of developing dementia (odds ratio [OR] 2.10, 95% confidence interval [CI] 1.01–4.37, p = 0.046) and the subtype stroke-related dementia (vascular dementia and mixed dementia) (OR 4.40, 95% CI 1.54–12.61, p = 0.006) than women not given supplementation (n = 602). In stratified analyses, calcium supplementation was associated with the development of dementia in groups with a history of stroke (OR 6.77, 95% CI 1.36–33.75, p = 0.020) or presence of white matter lesions (OR 2.99, 95% CI 1.28–6.96, p = 0.011), but not in groups without these conditions.

Conclusions:

Calcium supplementation may increase the risk of developing dementia in elderly women with cerebrovascular disease. Because our sample was relatively small and the study was observational, these findings need to be confirmed.

Get full access to this article

View all available purchase options and get full access to this article.

REFERENCES

1.
Skoog I, Nilsson L, Palmertz B, Andreasson LA, Svanborg A. A population-based study of dementia in 85-year-olds. N Engl J Med 1993;328:153–158.
2.
Bauer DC. Clinical practice: calcium supplements and fracture prevention. N Engl J Med 2013;369:1537–1543.
3.
Reid IR, Bristow SM, Bolland MJ. Calcium supplements: benefits and risks. J Intern Med 2015;278:354–368.
4.
Wang X, Chen H, Ouyang Y, et al. Dietary calcium intake and mortality risk from cardiovascular disease and all causes: a meta-analysis of prospective cohort studies. BMC Med 2014;12:158.
5.
Wang L, Manson JE, Song Y, Sesso HD. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 2010;152:315–323.
6.
Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011;342:d2040.
7.
Lewis JR, Calver J, Zhu K, Flicker L, Prince RL. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up. J Bone Miner Res 2011;26:35–41.
8.
Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007;115:846–854.
9.
Walker MD, Silverberg SJ. Cardiovascular aspects of primary hyperparathyroidism. J Endocrinol Invest 2008;31:925–931.
10.
Kloppenborg RP, van den Berg E, Kappelle LJ, Biessels GJ. Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur J Pharmacol 2008;585:97–108.
11.
Skoog I, Gustafson D. Hypertension, hypertension-clustering factors and Alzheimer's disease. Neurol Res 2003;25:675–680.
12.
Chung JW, Ryu WS, Kim BJ, Yoon BW. Elevated calcium after acute ischemic stroke: association with a poor short-term outcome and long-term mortality. J Stroke 2015;17:54–59.
13.
Kern S, Skoog I, Ostling S, Kern J, Borjesson-Hanson A. Does low-dose acetylsalicylic acid prevent cognitive decline in women with high cardiovascular risk? A 5-year follow-up of a non-demented population-based cohort of Swedish elderly women. BMJ Open 2012;2:1286–1288.
14.
Karlsson B, Klenfeldt IF, Sigstrom R, et al. Prevalence of social phobia in non-demented elderly from a Swedish population study. Am J Geriatr Psychiatry 2009;17:127–135.
15.
Simoni M, Pantoni L, Pracucci G, et al. Prevalence of CT-detected cerebral abnormalities in an elderly Swedish population sample. Acta Neurol Scand 2008;118:260–267.
16.
Skoog I, Palmertz B, Andreasson LA. The prevalence of white-matter lesions on computed tomography of the brain in demented and nondemented 85-year-olds. J Geriatr Psychiatry Neurol 1994;7:169–175.
17.
American Psychological Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed Washington, DC: American Psychological Association; 1987.
18.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939–944.
19.
Guo X, Waern M, Sjogren K, et al. Midlife respiratory function and incidence of Alzheimer's disease: a 29-year longitudinal study in women. Neurobiol Aging 2007;28:343–350.
20.
Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology 1993;43:250–260.
21.
Ostling S, Gustafson D, Blennow K, Borjesson-Hanson A, Waern M. Psychotic symptoms in a population-based sample of 85-year-old individuals with dementia. J Geriatr Psychiatry Neurol 2011;24:3–8.
22.
Moyer VA; US Preventive Services Task Force. Vitamin D and calcium supplementation to prevent fractures in adults: US Preventive Services Task Force recommendation statement. Ann Intern Med 2013;158:691–696.
23.
Augat P, Weyand D, Panzer S, Klier T. Osteoporosis prevalence and fracture characteristics in elderly female patients with fractures. Arch Orthop Trauma Surg 2010;130:1405–1410.
24.
Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;348:1215–1222.
25.
Linden T, Skoog I, Fagerberg B, Steen B, Blomstrand C. Cognitive impairment and dementia 20 months after stroke. Neuroepidemiology 2004;23:45–52.
26.
Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke 1997;28:652–659.
27.
Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010;341:c3691.
28.
Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med 2009;361:1570–1583.
29.
Zhivotovsky B, Orrenius S. Cell cycle and cell death in disease: past, present and future. J Intern Med 2010;268:395–409.
30.
Tomonaga M, Yamanouchi H, Tohgi H, Kameyama M. Clinicopathologic study of progressive subcortical vascular encephalopathy (Binswanger type) in the elderly. J Am Geriatr Soc 1982;30:524–529.
31.
Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004;24:1161–1170.
32.
Umesawa M, Iso H, Ishihara J, et al. Dietary calcium intake and risks of stroke, its subtypes, and coronary heart disease in Japanese: the JPHC Study Cohort I. Stroke 2008;39:2449–2456.
33.
Rossom RC, Espeland MA, Manson JE, et al. Calcium and vitamin D supplementation and cognitive impairment in the women's health initiative. J Am Geriatr Soc 2012;60:2197–2205.
34.
Payne ME, McQuoid DR, Steffens DC, Anderson JJ. Elevated brain lesion volumes in older adults who use calcium supplements: a cross-sectional clinical observational study. Br J Nutr 2014;112:220–227.
35.
Afzal S, Bojesen SE, Nordestgaard BG. Reduced 25-hydroxyvitamin D and risk of Alzheimer's disease and vascular dementia. Alzheimers Dement 2014;10:296–302.
36.
Bolland MJ, Grey A, Gamble GD, Reid IR. The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes Endocrinol 2014;2:307–320.
37.
Jacobs DR Jr, Hohe C, Mursu J, Robien K, Folsom AR. Whole grain intake, incident hip fracture and presumed frailty in the Iowa Women's Health Study. Br J Nutr 2010;104:1537–1543.
38.
Gudmundsson P, Olesen PJ, Simoni M, et al. White matter lesions and temporal lobe atrophy related to incidence of both dementia and major depression in 70-year-olds followed over 10 years. Eur J Neurol 2015;22:781–788, e49–e50.
39.
Lopez OL, Becker JT, Jungreis CA, et al. Computed tomography—but not magnetic resonance imaging—identified periventricular white-matter lesions predict symptomatic cerebrovascular disease in probable Alzheimer's disease. Arch Neurol 1995;52:659–664.
40.
Beynon R, Sterne JA, Wilcock G, et al. Is MRI better than CT for detecting a vascular component to dementia? A systematic review and meta-analysis. BMC Neurol 2012;12:33.
Letters to the Editor
28 October 2016
Author response to Dr. Beale
Silke Kern, MD, PhD
J. Kern; K. Blennow; H. Zetterberg; M. Waern; X. Guo; A. B?rjesson-Hanson; I. Skoog; S. ?stling

We thank Dr. Beale for the interesting comment on our article. [1] We agree that Vitamin D is a possible confounder. However, we did not detect a modifying effect of Vtiamin D in our study. Even if existing data are not sufficient to conclude that Vitamin D reduces dementia risk, an association was found between low plasma 25-hydroxy vitamin D and an increased risk of Alzheimer disease and vascular dementia. [2] Therefore, Vitamin D supplementation might even decrease the risk of dementia. As noted in our paper, the study was observational. Thus, true cause and effect cannot be proven.

1. Kern J, Kern S, Blennow K, et al. Calcium supplementation and risk of dementia in women with cerebrovascular disease. Neurology 2016;87:1674-1680.

2. Afzal S, Bojesen SE, Nordestgaard BG. Reduced 25-hydroxyvitamin D and risk of Alzheimer's disease and vascular dementia. Alzheimers Dement 2014;10:296-302.

For disclosures, please contact the editorial office at [email protected].

21 October 2016
Methodology leads to unreliable results
David J. Beale, Clinical Pharmacist

Kern et al. conducted a small, observational, retrospective, longitudinal, population-based cohort study of calcium supplementation and increased dementia risk in elderly women. [1] Women who took calcium supplementation had higher odds of dementia. However, the number of individuals taking calcium supplements without vitamin D was low and compromised the reliability of the results. The sample size (n=98) in the calcium supplements group included women taking calcium supplements with 85.7% (84 of 98) also taking vitamin D. [1] The authors, recognizing vitamin D as a confounding variable, included it in regression models and stated that vitamin D did not affect the "main results." [1] However, controlling for vitamin D would not improve statistical power. Women taking calcium supplements with vitamin D should have been excluded at baseline because the dependent variable in the hypothesis was calcium supplementation alone. [1] The calcium supplement group was described as "women treated with calcium supplements," [1] but they were actually women treated with calcium supplements most of whom took vitamin D. Thus, the study hypothesis of calcium supplementation association with an increased risk of dementia was tested with a small sample size of 98 where only 14 individuals were relevant to the research question.

1. Kern J, Kern S, Blennow K, et al. Calcium supplementation and risk of dementia in women with cerebrovascular disease. Neurolog. 2016;87:1674-1680.

For disclosures, please contact the editorial office at [email protected].

28 September 2016
Author Response to Dr. Rosenberg
Silke Kern, MD, PhD
J. Kern, K. Blennow, H. Zetterberg, M. Waern, X. Guo, A. Borjesson-Hanson, I. Skoog, S. Ostling

We thank Dr. Rosenberg for the interesting comment. Indeed, in our article, [1] we referenced Bolland et al. for an acute (steep) increase in serum calcium being one possible mechanism. [2] This acute increase is correctly detailed by Dr. Rosenberg, just to a modest degree. However, in the pathomechanism of cell death, the acute increase in itself, not the amount of the increase, might be important especially in vulnerable neurons already compromised by cerebrovascular disease. Additionally, there are several possible mechanisms of calcium supplements in the pathogenesis of dementia.

We agree with Dr. Rosenberg that further research should look for mechanisms outside the realm of calcium pharmacokinetics.

1. Kern J, Kern S, Blennow K, et al. Calcium supplementation and risk of dementia in women with cerebrovascular disease. Neurology Epub 2016 Aug 17.

2. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010;341:c3691.

For disclosures, please contact the editorial office at [email protected].

23 September 2016
Calcium-associated dementia risk
Gilad Rosenberg, Medical Director

Kern et al. reported calcium supplementation may increase the risk of dementia in elderly women with cerebrovascular disease. [1] Among the possible mechanisms that could explain this association, the authors mentioned "the steep increase in serum calcium levels caused by the supplements." [1] This statement was referenced to a previous publication, [2] which described the supplement-induced increase in serum calcium as "modest" based on the results of an earlier study in young healthy subjects. [3] A more recent study in overweight but otherwise healthy post-menopausal women administered a single dose of 500 mg elemental calcium supplement after pre-treatment with 10 micrograms 25(OH)D3 and found that the maximal increase in serum level of ionized calcium post-dosing was in the vicinity of 0.3 mg/dL (i.e. approximately only 5% of the upper limit of this ion's normal serum concentration); this change peaked 3 to 5 hours after the supplement's ingestion. [4] Such a small increase over several hours can hardly be termed "steep." The mechanism, if any, linking the increased dementia risk with calcium supplementation should probably be looked for outside the realm of calcium's pharmacokinetics.

1. Kern J, Kern S, Blennow K, et al. Calcium supplementation and risk of dementia in women with cerebrovascular disease. Neurology Epub 2016 Aug 17.

2. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010;341:c3691.

3. Reid IR, Schooler BA, Hannan SF, Ibbertson HK. The acute biochemical effects of four proprietary calcium preparations. Aust N Z J Med 1986;16:193-197.

4. Heaney RP, Dowell MS, Bierman J, Hale CA, Bendich A. Absorbability and cost effectiveness in calcium supplementation. J Am Coll Nutr 2001;20:239-246.

For disclosures, please contact the editorial office at [email protected].

Information & Authors

Information

Published In

Neurology®
Volume 87Number 16October 18, 2016
Pages: 1674-1680
PubMed: 27534711

Publication History

Received: January 16, 2016
Accepted: July 5, 2016
Published online: August 17, 2016
Published in print: October 18, 2016

Permissions

Request permissions for this article.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

Study Funding

This study was supported by grants from The Swedish Research Council (11267, 2005-8460, 825-2007-7462, 825-2012-5041, 2013-8717, 2013-61X-14002, 2015-02830); the Torsten Söderbergs Stiftelse at the Royal Swedish Academy of Sciences; Swedish Research Council for Health, Working Life and Wellfare (nos. 2001-2646, 2001-2835, 2003-0234, 2004-0150, 2006-0020, 2008-1229, 2004-0145, 2006-0596, 2008-1111, 2010-0870, AGECAP 2013-2300, 2013-2496, Epilife 2006-1506); Swedish Brain Power; The Alzheimer's Association Zenith Award (ZEN-01-3151); The Alzheimer's Association Stephanie B. Overstreet Scholars (IIRG-00-2159); The Knut and Alice Wallenberg Foundation; Sahlgrenska University Hospital (ALF); The Emil and Maria Palm Foundation; The Bank of Sweden Tercentenary Foundation; EU FP7 project LipiDiDiet; Grant Agreement 211696; Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse; Eivind och Elsa K:son Sylvans Stiftelse; Stiftelsen Söderström-Königska Sjukhemmet; Stiftelsen för Gamla Tjänarinnor; Handlanden Hjalmar Svenssons Forskningsfond; Stiftelsen Längmanska Kulturfonden; Epilife Small Grant; and Stiftelsen Demensfonden. None of the funders was involved in the design or interpretation of the study. The funding sources had no involvement in study design; the collection, analysis, or interpretation of data; the writing of the paper; or the decision to submit the paper for publication.

Authors

Affiliations & Disclosures

Jürgen Kern, MD, PhD*
From the Department of Neuropsychiatric Epidemiology (J.K., S.K., M.W., X.G., A.B.-H., I.S., S.O.) and Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology (S.K., K.B., H.Z.), Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and UCL Institute of Neurology (H.Z.), London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Silke Kern, MD, PhD*
From the Department of Neuropsychiatric Epidemiology (J.K., S.K., M.W., X.G., A.B.-H., I.S., S.O.) and Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology (S.K., K.B., H.Z.), Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and UCL Institute of Neurology (H.Z.), London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Associate Editor of Journal of Alzheimer's disease since 2016 without compensation.
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Kaj Blennow, MD, PhD
From the Department of Neuropsychiatric Epidemiology (J.K., S.K., M.W., X.G., A.B.-H., I.S., S.O.) and Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology (S.K., K.B., H.Z.), Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and UCL Institute of Neurology (H.Z.), London, UK.
Disclosure
Scientific Advisory Boards:
1.
Dr Blennow has served at advisory boards or as a consultant for Eli Lilly, IBL International, and Roche Diagnostics.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Fujirebio Europe
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Novartis
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
Co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
The Research Council, Sweden (project # 14002) and LUA/ALF project, V?stra G?talandsregionen, Sweden (project # ALFGBG-11019)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
The Torsten S?derberg Foundation at the royal Swedish Academy of Sciences, the Alzheimer Foundation, Sweden, the Stiftelsen f?r Gamla Tj?narinnor, Stockholm, Sweden and Hj?rnfonden, Sweden.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Henrik Zetterberg, MD, PhD
From the Department of Neuropsychiatric Epidemiology (J.K., S.K., M.W., X.G., A.B.-H., I.S., S.O.) and Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology (S.K., K.B., H.Z.), Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and UCL Institute of Neurology (H.Z.), London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Journal of Alzheimer's Disease, Associate Editor Alzheimer's & Dementia, Associate Editor DADM, Associate Senior Editor
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
HZ is co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg.
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) The Swedish Research Council (K2010-63P-21562-01-4, K2011-61X-20401-05-6); (2) Swedish State Support for Clinical Research (ALFGBG-144341); (3) VINNOVA; (4) the Knut and Alice Wallenberg Foundation; (5) the European Research Council; and (6) Frimurarestiftelsen
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Margda Waern, MD, PhD
From the Department of Neuropsychiatric Epidemiology (J.K., S.K., M.W., X.G., A.B.-H., I.S., S.O.) and Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology (S.K., K.B., H.Z.), Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and UCL Institute of Neurology (H.Z.), London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
Den suicidn?ra patienten (The suicidal patient). Studentlitteratur. receipt of royalties 2012-2016.
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Swedish Council for working life and social research Suicidal thoughts and attempts in women followed from mid- to late life. Grant number 2012-1138. PI. 2013-2014. Suicidality in suicide attempters. Swedish Research Council. grant number 2013-2699. PI 2014-2016. Suicidality in older women. King Gustaf V and Queen Victoria's Freemason Foundation. 2014-16. SCREAM: Acute suicidal episodes. Gothenburg Center for Person-centered Care. 2014. Suicidality in suicide attempters. Swedish Research Council. grant number 2011-299. PI 2012-2014. Sahlgrenska Studies on suicide. Swedish Research Council. grant number 2008-3139 Swedish Council for working life and social research A 41 year longitudinal population study on dementia and other disorders in women. Grant number 2008-1229.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Xinxin Guo, MD, PhD
From the Department of Neuropsychiatric Epidemiology (J.K., S.K., M.W., X.G., A.B.-H., I.S., S.O.) and Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology (S.K., K.B., H.Z.), Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and UCL Institute of Neurology (H.Z.), London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Anne Börjesson-Hanson, MD, PhD
From the Department of Neuropsychiatric Epidemiology (J.K., S.K., M.W., X.G., A.B.-H., I.S., S.O.) and Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology (S.K., K.B., H.Z.), Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and UCL Institute of Neurology (H.Z.), London, UK.
Disclosure
Scientific Advisory Boards:
1.
Served on advisory board or DSMB for Kyowa Hakko Kirin and Ionis
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Consultant for Pfizer, Janssen-Cilag, Lundbeck, Novartis
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
Serve as investigator for clinical trials sponsored by Lilly, Novartis, Pfizer, ACImmune, Sanofiaentis
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ingmar Skoog, MD, PhD
From the Department of Neuropsychiatric Epidemiology (J.K., S.K., M.W., X.G., A.B.-H., I.S., S.O.) and Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology (S.K., K.B., H.Z.), Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and UCL Institute of Neurology (H.Z.), London, UK.
Disclosure
Scientific Advisory Boards:
1.
Takeda
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Takeda Novartis
Editorial Boards:
1.
American Journal of Geriatric psychiatry. Triage-Editor 2010- European Journal of Psychiatry. Editorial Board
Patents:
1.
NONE
Publishing Royalties:
1.
Dementia textbook Sweden 2003. Liber Text book in acute psychiatri. Studentlitteratur
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Takeda
Speakers' Bureaus:
1.
Takeda
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1)The Swedish Research Council 11267, 825-2012-5041, 2013-8717, 2015-02830 PI 1994 until now (2) Swedish Research Council for Health, Working Life and Wellfare (2012-1138, 2013-1202, 2013-2300, 2013-2496, 2006-1506)PI, 1999 until now (3) Swedish Brain Power co-PI, 2005 until now
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
The Alzheimer's Association Zenith Award (ZEN-01-3151) The Alzheimer's Association Stephanie B. Overstreet Scholars (IIRG-00-2159) The Alzheimer's Association (IIRG-03-6168) The Bank of Sweden Tercentenary Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Svante Östling, MD, PhD
From the Department of Neuropsychiatric Epidemiology (J.K., S.K., M.W., X.G., A.B.-H., I.S., S.O.) and Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology (S.K., K.B., H.Z.), Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and UCL Institute of Neurology (H.Z.), London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
FAS 2013-0475 1.500.000 swedish kr
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
220.000 swedish kr. S?derstr?m K?nigska projektanslag
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence to Dr. S. Kern: [email protected]
*
These authors contributed equally to this work.
These authors share last authorship.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Author Contributions

Jürgen Kern and Silke Kern analyzed and interpreted the data, conducted the literature search, and wrote the paper. Kaj Blennow, Henrik Zetterberg, Margda Waern, Xinxin Guo, and Anne Börjesson-Hanson contributed with the analysis and interpretation of the data and revised the article critically for important intellectual content. Ingmar Skoog and Svante Östling conceived and designed the study, refined the study methods, were involved in analysis and interpretation of the data, and revised the article critically for important intellectual content. The corresponding author attests that the authors had access to all the study data, take responsibility for the accuracy of the analysis, and had authority over manuscript preparation and the decision to submit the manuscript for publication. All authors gave final approval of the version to be published. The corresponding author affirms that he has listed everyone who contributed significantly to the work.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Essential Nutrients and White Matter Hyperintensities: A Two-Sample Mendelian Randomization Study, Biomedicines, 12, 4, (810), (2024).https://doi.org/10.3390/biomedicines12040810
    Crossref
  2. Associations between plasma metal elements and risk of cognitive impairment among Chinese older adults, Frontiers in Aging Neuroscience, 16, (2024).https://doi.org/10.3389/fnagi.2024.1353286
    Crossref
  3. Micronutrients for Dementia Prevention, Nutrition in Brain Aging and Dementia, (151-165), (2024).https://doi.org/10.1007/978-981-97-4117-5_7
    Crossref
  4. Metals in Alzheimer’s Disease, Biomedicines, 11, 4, (1161), (2023).https://doi.org/10.3390/biomedicines11041161
    Crossref
  5. Oral calcium and vitamin D supplements differentially alter exploratory, anxiety-like behaviors and memory in male rats, PLOS ONE, 18, 8, (e0290106), (2023).https://doi.org/10.1371/journal.pone.0290106
    Crossref
  6. Habitual glucosamine use, APOE genotypes, and risk of incident cause-specific dementia in the older population, Alzheimer's Research & Therapy, 15, 1, (2023).https://doi.org/10.1186/s13195-023-01295-6
    Crossref
  7. Cerebrospinal fluid biomarkers of axonal and synaptic degeneration in a population-based sample, Alzheimer's Research & Therapy, 15, 1, (2023).https://doi.org/10.1186/s13195-023-01193-x
    Crossref
  8. Causal association of genetically determined circulating vitamin D metabolites and calcium with multiple sclerosis in participants of European descent, European Journal of Clinical Nutrition, 77, 4, (481-489), (2023).https://doi.org/10.1038/s41430-023-01260-4
    Crossref
  9. Role of calcium in Parkinson's disease, Vitamins and Minerals in Neurological Disorders, (561-577), (2023).https://doi.org/10.1016/B978-0-323-89835-5.00021-1
    Crossref
  10. A Metallomic Approach to Assess Associations of Plasma Metal Levels with Amnestic Mild Cognitive Impairment and Alzheimer’s Disease: An Exploratory Study, Journal of Clinical Medicine, 11, 13, (3655), (2022).https://doi.org/10.3390/jcm11133655
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share